Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint Jul. 17, 2023 5:04 PM ET Recursion Pharmaceuticals, Inc. (RXRX) Stock NVDA , RXRX 21 Comments 4 Likes Nelson Alves ...

Recursion has featured the performance of two generations of proprietary models trained on Recursion’s internal microscopy, Phenom-1 (CVPR 2024) and Phenom-2 (NeurIPS FM4S 2024).

Recursion Pharmaceuticals, Inc. With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio ...

--Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in ...